Effects of various absorption enhancers on transport of clodronate through Caco-2 cells

International Journal of Pharmaceutics

Volumn 261, Issue 1-2, 2003, Pages 129-136

  Raiman, Johanna ^a,c   Törmälehto, Soili ^a   Yritys, Kirsi ^a   Junginger, Hans E ^b   Mönkkönen, Jukka ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Absorption; Absorption enhancers; Bisphosphonates; Caco 2 cells; Clodronate

Indexed keywords

CALCIUM; CHLORIDE; CLODRONIC ACID; DECANOATE SODIUM; EGTAZIC ACID; N TRIMETHYLCHITOSAN CHLORIDE; PALMITOYLCARNITINE; PALMITOYLCARNITINE CHLORIDE; SODIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL STRAIN CACO 2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFECT; DRUG POTENCY; DRUG TRANSPORT; EXPERIMENTAL TEST; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; RAT; TIGHT JUNCTION;

EID: 0042527106     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00300-4     Document Type: Article

References (31)

1. Ahlmark M., Vepsäläinen J., Taipale H., Niemi R., Järvinen T. Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate. J. Med. Chem. 42:1999;1473-1476.
2. Artursson P., Magnusson C. Epithelial transport of drugs in cell culture. II. Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 79:1990;595-600.
3. Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 22:1996;67-84.
4. Boulenc X., Marti E., Joyeux H., Roques C., Berger Y., Fabre G. Importance of the paracellular pathway for the transport of a new bisphosphonate using the human Caco-2 monolayers model. Biochem. Pharmacol. 46:1993;1591-1600.
5. Boulenc X., Breul T., Gautier J.-C., Saudemon P., Joyeux H., Roques C., Berger Y., Fabre G. Sodium lauryl sulphate increases tiludronate paracellular transport using human epithelial Caco-2 monolayers. Int. J. Pharm. 123:1995a;71-83.
6. Boulenc X., Roques C., Joyeux H., Berger Y., Fabre G. Bisphosphonates increase tight junction permeability in the human intestinal epithelial (Caco-2) model. Int. J. Pharm. 123:1995b;13-24.
7. 2+ in cultured epithelia. Biochim. Biophys. Acta. 1222:1994;147-158.
8. Duizer E., Van der Wulp C., Versantvoort C.H.M., Groten J.P. Absorption enhancement, structural changes in tight junctions and cytotoxicity caused by palmitoyl carnitine in Caco-2 and IEC-18 cells. J. Pharmacol. Exp. Ther. 287:1998;395-402.
9. Ezra A., Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv. Drug Deliv. Rev. 42:2000;175-195.
10. Ezra A., Hoffman A., Breuer E., Alferiev I.S., Mönkkönen J., El Hanany-Rozen N., Weiss G., Stepensky D., Gati I., Cohen H., Törmälehto S., Amidon G.L., Golomb G. A peptide prodrug approach for improving bisphosphonate oral absorption. J. Med. Chem. 43:2000;3641-3652.
11. Fleisch, H., 1997. Bisphosphonates in Bone Disease. From the Laboratory to the Patient, 3rd ed. The Parthenon Publishing Group, New York.
12. Fogelman I., Smith L., Mazess R., Wilson M.A., Bevan J.A. Absorption of oral diphosphonate in normal subjects. Clin. Endocrinol. 24:1986;57-62.
13. Hochman J.H., Fix J.A., LeCluyse L. In vitro and in vivo analysis of the mechanism of absorption enhancement by palmitoylcarnitine. J. Pharm. Exp. Ther. 269:1994;813-822.
14. Janner M., Mühlbauer R.C., Fleisch F. Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif. Tissue Int. 49:1991;280-283.
15. Kotzé A.F., Lueßen H.L., de Leeuw B.J., de Boer A.G., Verhoef J.C., Junginger H.E. N-Trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm. Res. 14:1997;1197-1202.
16. Laitinen K., Patronen A., Harju P., Löyttyniemi E., Pylkkänen L., Kleimola T., Perttunen K. Timing of food intake has a marked effect on the bioavailability of clodronate. Bone. 27:2000;293-296.
17. LeCluyse E.L., Sutton S.C. In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement. Adv. Drug Deliv. Rev. 23:1997;163-183.
18. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 18:1996;75-85.
19. Lindmark T., Kimura Y., Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 284:1998;362-369.
20. Nicklin P.L., Irwin W.J., Hassan I.F., Mackay M. Development of a minimum-calcium Caco-2 monolayer model: calcium and magnesium ions retard the transport of pamidronate. Int. J. Pharm. 123:1995;187-197.
21. Niemi R., Vepsäläinen J., Taipale H., Järvinen T. Bisphosphonate prodrugs: synthesis and an vitro evaluation of novel acyloxyalkyl esters of clodronic acid. J. Med. Chem. 42:1999;5053-5058.
22. Niemi R., Turhanen P., Vepsäläinen J., Taipale H., Järvinen T. Bisphosphonate prodrugs: synthesis and in vitro evaluation of alkyl and acyloxymethyl esters of etidronic acid as bioreversible prodrugs of etidronate. Eur. J. Pharm. Sci. 11:2000;173-180.
23. Noach A.B.J., Kurosaki Y., Blom-Roosemalen M.C.M., de Boer A.G., Breimer D.D. Cell-polarity dependent effect of chelation on the paracellular permeability of confluent Caco-2 cell monolayers. Int. J. Pharm. 90:1993;229-237.
24. Pentikäinen P.J., Elomaa I., Nurmi A.-K., Kärkkäinen S. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int. J. Clin. Pharmacol. Ther. Toxicol. 27:1989;222-228.
25. Plosker G.L., Goa K.L. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 47:1994;945-982.
26. Raiman J., Niemi R., Vepsäläinen J., Yritys K., Järvinen T., Mönkkönen J. Effects of calcium and lipophilicity on transport of clodronate and its esters through Caco-2 cells. Int. J. Pharm. 213:2001;135-142.
27. Sakai M., Imai T., Ohtake H., Otagiri M. Cytotoxicity of absorption enhancers in Caco-2 cell monolayers. J. Pharm. Pharmacol. 50:1998;1101-1108.
28. Twiss I.M., de Water R., den Hartigh J., Sparidans R., Ramp-Koopmanschap W., Brill H., Wijdeveld M., Vermeij P. Cytotoxic effects of pamidronate on monolayers on human intestinal epithelial (Caco-2) cells and its epithelial transport. J. Pharm. Sci. 83:1994;699-703.
29. Van Hoogdalem E.J., Wackwitz A.T.E., de Boer A.G., Breimer D.D. 3-Amino-1-hydroxypropylidene-1,1-diphosphonate (APD): a novel enhancer of rectal cefoxitin absorption in rats. J. Pharm. Pharmacol. 41:1989;339-341.
30. Villikka K., Perttunen K., Rosnell J., Ikävalko H., Vaho H., Pylkkänen L. The absolute bioavailability of clodronate from two different oral doses. Bone. 31:2002;418-421.
31. Yakatan G.J., Poynor W.J., Talbert R.L., Floyd B.F., Slough C.L., Ampulski R.S., Benedict J.J. Clodronate kinetics and bioavailability. Clin. Pharmacol. Ther. 31:1982;402-410.